Fändrich Fred, Ruhnke Maren
Klinik für Allgemeine Chirurgie und Thoraxchirurgie, Universitätsklinikum Schleswig-Holstein, Campus Kiel.
Med Klin (Munich). 2003 Dec 15;98 Suppl 2:18-22.
Reproducible stem cell programmability, either embryonic or adult in nature, will open a variety of clinical application strategies for the treatment of tissue injuries, degenerated organs and body components, respectively, in the future. In addition, stem cells will be used to complement metabolically or genetically caused diseases. Pluripotent plasticity of stem cells describes their ability to be programmed into target cells encountered in all three germ layers during embryologic development. Here, we review future application modalities for the clinical use of cellular-derived products and therapeutics for patients presenting with liver diseases. This overview is designed as a state-of-the-art survey taking into account current knowledge and published work. It includes a diversified description of biological advantages and disadvantages of different types of stem cells, considers related ethical aspects and outlines clinically required parameters for the use of stem cells in humans. Successful application of stem cell-associated therapeutics in man will be closely related with ensuing patient risk profiles, stringent indications, long-term patient outcomes and will be determined by cost-benefit efficacy.
可重现的干细胞可编程性,无论其来源是胚胎干细胞还是成体干细胞,都将在未来分别为治疗组织损伤、退化器官和身体组成部分开启多种临床应用策略。此外,干细胞还将用于补充代谢性或遗传性疾病的治疗。干细胞的多能可塑性描述了它们在胚胎发育过程中被编程为所有三个胚层中所遇到的靶细胞的能力。在此,我们综述了细胞衍生产品和治疗方法在肝病患者临床应用中的未来应用模式。本综述旨在作为一项考虑到当前知识和已发表研究的最新调查。它包括对不同类型干细胞的生物学优缺点的多样化描述,考虑了相关伦理问题,并概述了在人体中使用干细胞所需的临床参数。干细胞相关治疗方法在人体中的成功应用将与随之而来的患者风险状况、严格的适应症、患者长期预后密切相关,并将由成本效益疗效决定。